A Phase 2 interventional study of CSL787 and Placebo in Non-cystic Fibrosis Bronchiectasis, sponsored by CSL Behring. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Inflammation with a site in Japan — 3 open to participants now, 4 under way, none of them phase 3. Inflammation · Japan.
Among the 16 studies in Inflammation with a site in Japan, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 16th registered.
3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.
Browse Inflammation studies →3 of the 16 studies in Inflammation with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Belgium and 19 more countries
Ages 6–100
Federal University of São Paulo · Sites in Japan, Argentina, Brazil and 5 more countries
Ages 18–75 · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 50 across 2,582 interventional studies indexed under Inflammation.
Median enrollment 120 across the 13 interventional studies, 974 across the 3 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Inflammation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Inflammation with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (human normal immunoglobulin G [IgG] inhalation solution) compared with placebo over 52 weeks.
The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the time to first (TTF) exacerbation.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a high dose of CSL787.
Biological: CSL787 · Device: Nebulizer
Participants in this arm will receive a low dose of CSL787.
Biological: CSL787 · Device: Nebulizer
Participants in this arm will receive placebo.
Drug: Placebo · Device: Nebulizer
CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.
Participants will receive a matching volume of placebo QD over a period of 52 weeks.
The nebulizer is a CE-marked device.
Time to first (TTF) Exacerbation
TTF exacerbation, where an exacerbation is defined as a deterioration in ≥ 3 of the following symptoms for ≥ 48 hours: cough; sputum volume and / or consistency; sputum purulence; breathlessness and / or exercise tolerance; fatigue and / or malaise; hemoptysis AND a clinician determines that antibiotic therapy is required.
Time frame: Up to Week 52
Number of exacerbations over the Treatment and Observation Period
Time frame: Up to Week 52
Number of Participants Achieving a Minimally Clinically Important Difference (MCID) in the Quality of Life-Bronchiectasis (QoL-B) Respiratory Symptoms Scale
The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.
Time frame: Up to Week 52
Percentage of Participants Achieving a MCID in the QoL-B Respiratory Symptoms Scale
The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.
Time frame: Up to Week 52
Change From Baseline in QoL-B Respiratory Symptoms Scale
The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.
Time frame: Baseline to Week 52
Change From Baseline in Total Colony-forming Unit (CFUs) for Pathogenic Bacteria Isolated from Sputum
Time frame: Baseline up to Week 52
Number of Participants with Treatment-emergent Adverse events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up to Week 56
Percentage of Participants with TEAEs and SAEs
Time frame: Up to Week 56
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (i.e. FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for May 2029, 44 months after the start.
Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 44 months is above that.
Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Feb 2028 → May 2029 and completion Mar 2028 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous